156 related articles for article (PubMed ID: 17631131)
1. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
[TBL] [Abstract][Full Text] [Related]
2. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
Hawkey CJ; Weinstein WM; Stricker K; Murphy V; Richard D; Krammer G; Rebuli R
Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Bannwarth B; Berenbaum F
Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
[TBL] [Abstract][Full Text] [Related]
10. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
12. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Bello AE; Kent JD; Grahn AY; Rice P; Holt RJ
Postgrad Med; 2014 Jul; 126(4):82-91. PubMed ID: 25141246
[TBL] [Abstract][Full Text] [Related]
13. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
14. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
Scheiman JM; Yeomans ND; Talley NJ; Vakil N; Chan FK; Tulassay Z; Rainoldi JL; Szczepanski L; Ung KA; Kleczkowski D; Ahlbom H; Naesdal J; Hawkey C
Am J Gastroenterol; 2006 Apr; 101(4):701-10. PubMed ID: 16494585
[TBL] [Abstract][Full Text] [Related]
15. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
16. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
García Rodríguez LA; Barreales Tolosa L
Gastroenterology; 2007 Feb; 132(2):498-506. PubMed ID: 17258728
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
18. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
19. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Farkouh ME; Verheugt FW; Ruland S; Kirshner H; Jeger R; Gitton X; Krammer G; Stricker K; Sallstig P; Mellein B; Matchaba P; Chesebro JH
J Clin Hypertens (Greenwich); 2008 Aug; 10(8):592-602. PubMed ID: 18772641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
